| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P2093 | author name string | Ogawa M | |
| Takahashi T | |||
| Hamajima N | |||
| Mitsudomi T | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| meta-analysis | Q815382 | ||
| lung cancer | Q47912 | ||
| P304 | page(s) | 4055-4063 | |
| P577 | publication date | 2000-10-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis | |
| P478 | volume | 6 |
| Q80564893 | A TP53-truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome |
| Q35042319 | A novel differential diagnostic model for multiple primary lung cancer: Differentially-expressed gene analysis of multiple primary lung cancer and intrapulmonary metastasis |
| Q35141514 | Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells |
| Q35587286 | Analysis of cell cycle regulator proteins in non-small cell lung cancer |
| Q52647921 | Aqueous extract of Sapindus mukorossi induced cell death of A549 cells and exhibited antitumor property in vivo. |
| Q35200402 | Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer? |
| Q42363905 | Assessment of cell proliferation in renal cell carcinoma using dual-phase (18)F-fluorodeoxyglucose PET/CT |
| Q39403723 | Association of p53 codon 72 polymorphism and survival of North Indian lung cancer patients treated with platinum-based chemotherapy |
| Q34623884 | Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions |
| Q37342919 | Biomarkers in lung cancer: from early detection to novel therapeutics and decision making |
| Q24801522 | Can gene expression profiling predict survival for patients with squamous cell carcinoma of the lung? |
| Q35588677 | Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer |
| Q35556136 | Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: a prospective study |
| Q51146037 | Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer. |
| Q37126082 | Combination of p53AIP1 and survivin expression is a powerful prognostic marker in non-small cell lung cancer |
| Q37175551 | Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy |
| Q55369025 | Correlation and prognostic significance of PD-L1 and P53 expression in resected primary pulmonary lymphoepithelioma-like carcinoma. |
| Q35032319 | Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer |
| Q57174616 | Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients |
| Q42149046 | Expression of anti-apoptotic protein survivin and tumor suppressor p53 protein in patients with pulmonary carcinoma. |
| Q49901846 | Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing |
| Q36184584 | Genetic and biochemical alterations in non-small cell lung cancer |
| Q58802460 | Genomic instability in mutant p53 cancer cells upon entotic engulfment |
| Q89634774 | Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe? |
| Q35146944 | How close are we to customizing chemotherapy in early non-small cell lung cancer? |
| Q36049618 | Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590. |
| Q35770249 | Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation |
| Q37619114 | Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer |
| Q92716661 | Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer |
| Q36697794 | Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis |
| Q91605382 | Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer |
| Q28303718 | International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma |
| Q33972805 | Lung cancer * 9: Molecular biology of lung cancer: clinical implications |
| Q35179160 | Lung cancer incidence and survival in chromium exposed individuals with respect to expression of anti-apoptotic protein survivin and tumor suppressor P53 protein. |
| Q38633269 | Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity |
| Q64098209 | Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort |
| Q57807148 | Molecular evaluation of glutathione S transferase family genes in patients with sporadic colorectal cancer |
| Q35828688 | Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma. |
| Q92155015 | Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications |
| Q33688872 | Molecular pathways and therapeutic targets in lung cancer |
| Q64935425 | Mutation Frequencies in Endometrial Cancer Patients of Different Ethnicities and Tumor Grades: An Analytical Study. |
| Q36188758 | Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer |
| Q47132908 | Non-small cell lung carcinoma: cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins expression in resected tumors |
| Q38233321 | Non-small-cell lung cancers: a heterogeneous set of diseases |
| Q40515094 | Overexpression of G protein-coupled receptor 87 correlates with poorer tumor differentiation and higher tumor proliferation in non-small-cell lung cancer |
| Q36308536 | P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection |
| Q34781290 | PICT1 expression is a poor prognostic factor in non-small cell lung cancer |
| Q37929588 | Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables |
| Q36421289 | Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. |
| Q35810123 | Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature |
| Q82213597 | Risk of recurrence in surgically resected stage I adenocarcinoma of the lung: histopathologic and immunohistochemical analysis |
| Q37690890 | Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer |
| Q27014977 | Smoking, p53 mutation, and lung cancer |
| Q35220347 | Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites |
| Q38207312 | Standardized decision support in next generation sequencing reports of somatic cancer variants |
| Q36621221 | Sunlight may increase the FDG uptake value in primary tumors of patients with non-small cell lung cancer |
| Q36616469 | Survival following lobectomy vs limited resection for stage I lung cancer: a meta-analysis |
| Q36311791 | Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis |
| Q89793203 | TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC |
| Q37581666 | TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis |
| Q34559185 | TP53 mutations in nonsmall cell lung cancer |
| Q36128449 | Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA |
| Q35536290 | The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. |
| Q38021407 | The impact of E-cadherin expression on non-small cell lung cancer survival: a meta-analysis |
| Q34668320 | The prognostic molecular markers in hepatocellular carcinoma |
| Q36626149 | The relationship between aberrant methylation and survival in non-small-cell lung cancers |
| Q36642700 | The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC. |
| Q28392478 | Tumor suppressors and cell-cycle proteins in lung cancer |
| Q35848114 | Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status |
| Q36536565 | Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer |
| Q53686708 | YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting. |
| Q53639994 | [Clinical significance of mutant p53 protein expression in lung adenocarcinoma]. |
Search more.